Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen ‘s UK distributor, for the supply of SynGen’s products and all post-sales support, starting late summer 2015.
The state-of-the-art SynGenX-1000 System harvests the stem and progenitor cells from collected units of umbilical cord blood.
The CryoPRO Workstation protects the precious cells as they are prepared for freezing and storage in the novel CryoPRO-2 Cryopreservation/Storage Bag Set. The SynGenX-1000 System has received 510(k) clearance from the FDA for sale in the United States, and is CE marked for sale in the UK and the European Union.
"In our hands, the SynGen system demonstrated the highest recovery of viable stem and progenitor cells of the available systems," said Dr. Susana Gomez, Head of the Anthony Nolan Cord Blood Bank and Senior Research Scientist.
"We are proud to be associated with the prestigious Anthony Nolan Cell Therapy Centre and are pleased that their testing has demonstrated both high total nuclear cell counts (TNCs) and virtually 100% recoveries of critical CD 34+ cells in the final product using the SynGenX-1000 System," said Frank Pascale, President of the SynGen Cord Blood Business Unit.
"We look forward to supporting Anthony Nolan’s goal of providing them with the best possible cord blood units for transplant."
Anthony Nolan is a non-profit charity that saves the lives of people with blood cancer by matching remarkable people willing to donate their bone marrow or cord blood to patients in desperate need of a transplant.
Opened in 2008 by the UK Secretary of State for Health in the grounds of Nottingham Trent University, the Anthony Nolan Cell Therapy Centre is the first to combine cord blood storage with a research institute developing new techniques to use it.
The Anthony Nolan Cell Therapy Centre processes and stores cord blood for national and international clinical transplantation centres. The centre also carries out world-class research using blood of non-clinical standard, and supplies cord blood to other approved research programmes throughout Europe.
